DYN
Dyne Therapeutics, Inc.
Latest Form 4:Sale$47KbyLucera Erick (Chief Financial Officer) · filed Aug 17, 2026
Dyne Therapeutics, Inc. (DYN) has 50 SEC Form 4 filings (134 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Aug 17, 2026.
The most active filer is Director Rhodes Jason P with 19 filings. Insiders have net sold $168.0M over the trailing 6 months.
- Industry:Biotechnology
- CEO:John G. Cox
- Employees:192
- HQ:Waltham, MA, US
- IPO:2020-09-17
Insider Buying
$275K
reported purchases (SEC code P)
Insider Selling
$168.5M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Market Cap
$4.7B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Financial Officer | Sale | 1,797 | $47K | Aug 17 | SEC ↗ | |
| CEO & President | Sale | 4,986 | $131K | Aug 17 | SEC ↗ | |
| Chief Medical Officer | Sale | 1,556 | $41K | Aug 17 | SEC ↗ | |
| Director | Sale | 426,412 | $11.2M | Aug 17 | SEC ↗ | |
| Director | Sale | 2,160,516 | $54.0M | Aug 17 | SEC ↗ | |
| Chief Commercial Officer | Sale | 226 | $6K | Aug 17 | SEC ↗ | |
| Director | Sale | 261,460 | $6.7M | Jul 29 | SEC ↗ | |
| Director | Sale | 480,240 | $10.9M | Jul 8 | SEC ↗ | |
| Director | Sale | 297,211 | $6.9M | Jul 8 | SEC ↗ | |
| Director | Sale | 309,268 | $6.6M | Jun 30 | SEC ↗ | |
| Director | Sale | 195,427 | $4.1M | Jun 30 | SEC ↗ | |
| Director | Sale | 147,760 | $3.1M | Jun 26 | SEC ↗ | |
| Director | Sale | 95,900 | $2.0M | Jun 26 | SEC ↗ | |
| Director | Sale | 24,100 | $509K | Jun 26 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,362 | $48K | Jun 26 | SEC ↗ | |
| Director | Sale | 190,676 | $3.9M | Jun 24 | SEC ↗ | |
| Director | Sale | 73,286 | $1.5M | Jun 24 | SEC ↗ | |
| Director | Sale | 37,454 | $754K | Jun 22 | SEC ↗ | |
| Director | Sale | 46,901 | $941K | Jun 22 | SEC ↗ | |
| Chief Commercial Officer | Sale | 145 | $3K | Jun 17 | SEC ↗ | |
| CEO & President | Sale | 2,683 | $49K | Jun 17 | SEC ↗ | |
| Chief Medical Officer | Sale | 887 | $16K | Jun 17 | SEC ↗ | |
| Director | Purchase | 2,000 | $34K | Jun 9 | SEC ↗ | |
| Director | Purchase | 2,500 | $44K | Jun 5 | SEC ↗ | |
| Director | Purchase | 2,000 | $36K | May 28 | SEC ↗ | |
| Director | Purchase | 2,500 | $43K | May 22 | SEC ↗ | |
| CEO & President | Sale | 3,311 | $61K | May 14 | SEC ↗ | |
| Chief Commercial Officer | Sale | 228 | $4K | May 14 | SEC ↗ | |
| Chief Medical Officer | Sale | 1,564 | $29K | May 14 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,448 | $27K | May 14 | SEC ↗ | |
| Director | Sale | 11,904 | $214K | May 6 | SEC ↗ | |
| Director | Sale | 11,600 | $209K | May 6 | SEC ↗ | |
| Director | Sale | 83,219 | $1.5M | May 6 | SEC ↗ | |
| Director | Sale | 227,337 | $4.2M | Apr 30 | SEC ↗ | |
| Insider | Sale | 73,108 | $1.4M | Apr 27 | SEC ↗ | |
| Insider | Sale | 137,948 | $2.5M | Apr 27 | SEC ↗ | |
| Insider | Sale | 173,493 | $3.1M | Apr 27 | SEC ↗ | |
| Director | Sale | 8,300 | $166K | Apr 23 | SEC ↗ | |
| Director | Sale | 2,652 | $53K | Apr 23 | SEC ↗ | |
Rhodes Jason PFirst filing | Insider | Sale | 272,049 | $5.5M | Apr 22 | SEC ↗ |
Rhodes Jason PFirst filing | Insider | Sale | 274,297 | $5.4M | Apr 22 | SEC ↗ |
Rhodes Jason PFirst filing | Insider | Sale | 287,956 | $5.7M | Apr 22 | SEC ↗ |
| Director | Sale | 211,974 | $4.3M | Apr 21 | SEC ↗ | |
| Director | Sale | 125,274 | $2.5M | Apr 21 | SEC ↗ | |
| Director | Sale | 81,840 | $1.7M | Apr 17 | SEC ↗ | |
| Director | Sale | 17,773 | $368K | Apr 17 | SEC ↗ | |
Lucera ErickFirst filing | Chief Financial Officer | Sale | 5,727 | $107K | Apr 3 | SEC ↗ |
| Director | Purchase | 2,000 | $34K | Apr 1 | SEC ↗ | |
| Director | Sale | 129,672 | $2.5M | Mar 13 | SEC ↗ | |
| Director | Purchase | 2,000 | $39K | Mar 13 | SEC ↗ | |
Kersten DirkFirst filing | Director | Sale | 177,690 | $3.1M | Mar 11 | SEC ↗ |
Kersten DirkFirst filing | Director | Sale | 511,098 | $10.0M | Mar 11 | SEC ↗ |
Posner Brian SFirst filing | Director | Purchase | 3,000 | $45K | Mar 10 | SEC ↗ |
Cox JohnFirst in 3 months | CEO & President | Sale | 2,732 | $41K | Mar 6 | SEC ↗ |
Friedl-Naderer JohannaFirst in 3 months | Chief Commercial Officer | Sale | 148 | $2K | Mar 6 | SEC ↗ |
Kerr DouglasFirst in 3 months | Chief Medical Officer | Sale | 904 | $13K | Mar 6 | SEC ↗ |
| Chief Medical Officer | Sale | 880 | $18K | Dec 5 | SEC ↗ | |
| CEO & President | Sale | 2,662 | $55K | Dec 5 | SEC ↗ | |
| Chief Commercial Officer | Sale | 144 | $3K | Dec 5 | SEC ↗ | |
Cox JohnFirst filing | CEO & President | Sale | 2,640 | $35K | Sep 9 | SEC ↗ |
Kerr DouglasFirst filing | Chief Medical Officer | Sale | 3,552 | $47K | Sep 8 | SEC ↗ |
Kerr DouglasFirst filing | Chief Medical Officer | Sale | 873 | $12K | Sep 8 | SEC ↗ |
Friedl-Naderer JohannaFirst filing | Chief Commercial Officer | Sale | 894 | $12K | Sep 8 | SEC ↗ |
Friedl-Naderer JohannaFirst filing | Chief Commercial Officer | Sale | 144 | $2K | Sep 8 | SEC ↗ |
Related companies
Dyne Therapeutics, Inc. is in the Healthcare sector.